WO2000006759A3 - Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same - Google Patents

Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same Download PDF

Info

Publication number
WO2000006759A3
WO2000006759A3 PCT/US1999/016388 US9916388W WO0006759A3 WO 2000006759 A3 WO2000006759 A3 WO 2000006759A3 US 9916388 W US9916388 W US 9916388W WO 0006759 A3 WO0006759 A3 WO 0006759A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
constructs
delivery
angiogenesis
plasmids
Prior art date
Application number
PCT/US1999/016388
Other languages
French (fr)
Other versions
WO2000006759A2 (en
WO2000006759A9 (en
Inventor
Wang Min
Paul Szymanski
Dorothy Mehrens
Robert Ralston
Sean Sullivan
Original Assignee
Valentis Inc
Wang Min
Paul Szymanski
Dorothy Mehrens
Robert Ralston
Sean Sullivan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valentis Inc, Wang Min, Paul Szymanski, Dorothy Mehrens, Robert Ralston, Sean Sullivan filed Critical Valentis Inc
Priority to JP2000562541A priority Critical patent/JP2002524036A/en
Priority to EP99938769A priority patent/EP1100941A2/en
Priority to CA002337496A priority patent/CA2337496A1/en
Priority to AU53182/99A priority patent/AU5318299A/en
Publication of WO2000006759A2 publication Critical patent/WO2000006759A2/en
Publication of WO2000006759A3 publication Critical patent/WO2000006759A3/en
Publication of WO2000006759A9 publication Critical patent/WO2000006759A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to gene delivery and gene therapy, and provides novel nucleic acid constructs for expression of anti-angiogenic agents in a mammal, formualtions for delivery that incorporate a nucleic acid construct for expression, and methods for preparing and using such constructs and formulations. In particular, this invention relates to plasmid constructs for delivery of therapeutic anti-angiogenic encoding nucleic acids to cells in order to modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as cytokines, preferably IL-12), as well as methods for preparing such constructs.
PCT/US1999/016388 1998-07-27 1999-07-20 Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same WO2000006759A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000562541A JP2002524036A (en) 1998-07-27 1999-07-20 Anti-angiogenic plasmids and delivery systems and methods of making and using same
EP99938769A EP1100941A2 (en) 1998-07-27 1999-07-20 Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
CA002337496A CA2337496A1 (en) 1998-07-27 1999-07-20 Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
AU53182/99A AU5318299A (en) 1998-07-27 1999-07-20 Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9437598P 1998-07-27 1998-07-27
US60/094,375 1998-07-27

Publications (3)

Publication Number Publication Date
WO2000006759A2 WO2000006759A2 (en) 2000-02-10
WO2000006759A3 true WO2000006759A3 (en) 2000-06-22
WO2000006759A9 WO2000006759A9 (en) 2002-04-25

Family

ID=22244796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/016388 WO2000006759A2 (en) 1998-07-27 1999-07-20 Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same

Country Status (5)

Country Link
EP (1) EP1100941A2 (en)
JP (1) JP2002524036A (en)
AU (1) AU5318299A (en)
CA (1) CA2337496A1 (en)
WO (1) WO2000006759A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047235A2 (en) * 1999-02-10 2000-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of stimulating angiogenesis
ES2164011B1 (en) * 2000-02-25 2003-05-16 Inst Cientifico Tecnol Navarra COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS.
AU8591901A (en) 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
CN1531422A (en) * 2000-10-20 2004-09-22 Gene delivery formulations and methods for treatment of ischemic conditions
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7067649B2 (en) * 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
EP2223932A1 (en) 2001-10-19 2010-09-01 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
WO2003106636A2 (en) * 2002-06-14 2003-12-24 Mirus Corporation Novel methods for the delivery of polynucleotides to cells
EP3608426A1 (en) * 2018-08-10 2020-02-12 Pantherna Therapeutics GmbH Recombinant nucleic acid construct
ES2970185T3 (en) * 2018-08-10 2024-05-27 Pantherna Therapeutics Gmbh Recombinant nucleic acid construct

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006940A1 (en) * 1994-08-26 1996-03-07 Hoechst Aktiengesellschaft Genetic therapy of tumours with an endothelium cell-specific active substance which is dependent on the cell cycle
WO1997015666A1 (en) * 1995-10-23 1997-05-01 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
EP0819758A2 (en) * 1996-07-16 1998-01-21 Archibald James Mixson Cationic vehicle: DNA complexes and their use in gene therapy
EP0921193A1 (en) * 1997-12-05 1999-06-09 Archibald James Mixson Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006940A1 (en) * 1994-08-26 1996-03-07 Hoechst Aktiengesellschaft Genetic therapy of tumours with an endothelium cell-specific active substance which is dependent on the cell cycle
WO1997015666A1 (en) * 1995-10-23 1997-05-01 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
EP0819758A2 (en) * 1996-07-16 1998-01-21 Archibald James Mixson Cationic vehicle: DNA complexes and their use in gene therapy
EP0921193A1 (en) * 1997-12-05 1999-06-09 Archibald James Mixson Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BLEZINGER P ET AL: "Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases.", HUMAN GENE THERAPY, (1999 MAR 20) 10 (5) 723-31., XP000862836 *
BLEZINGER P ET AL: "Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene.", NATURE BIOTECHNOLOGY, (1999 APR) 17 (4) 343-8., XP000857410 *
BOEHM T ET AL: "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [see comments].", NATURE, (1997 NOV 27) 390 (6658) 404-7., XP000857413 *
CHEN Q R ET AL: "Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice.", CANCER RESEARCH, (1999 JUL 15) 59 (14) 3308-12., XP000857407 *
MUMPER R J ET AL: "Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle", JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 52, no. 1-2, pages 191-203, XP004113667, ISSN: 0168-3659 *
O'REILLY M ET AL: "ANGIOSTATIN A NOVEL ANGIOGENESIS INHIBITOR THAT MEDIATES THE SUPPRESSION OF METASTASES BY A LEWIS LUNG CARCINOMA", CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 79, pages 315-328, XP002015254, ISSN: 0092-8674 *
O'REILLY M S ET AL: "ENDOSTATIN: AN ENDOGENOUS INHIBITOR OF ANGIOGENESIS AND TUMOR GROWTH", CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 88, no. 2, pages 277-285, XP000652213, ISSN: 0092-8674 *
THURSTON G ET AL: "Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 101, 1 April 1998 (1998-04-01), pages 1401 - 1403, XP000863045 *

Also Published As

Publication number Publication date
EP1100941A2 (en) 2001-05-23
JP2002524036A (en) 2002-08-06
CA2337496A1 (en) 2000-02-10
WO2000006759A2 (en) 2000-02-10
AU5318299A (en) 2000-02-21

Similar Documents

Publication Publication Date Title
WO2000006759A3 (en) Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
WO1999047678A3 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same
AU5788096A (en) Plasmid for delivery of nucleic acids to cells and methods of use
CA3023101C (en) Modification of rna, producing an increased transcript stability and translation efficiency
EP0807183B1 (en) Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle
NO962791D0 (en) Preparations containing nucleic acids, their preparation and use
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
WO1999005300A3 (en) Ghrh expression system and methods of use
WO1999018933A3 (en) Methods for encapsulating nucleic acids in lipid bilayers
WO2001079442A3 (en) Albumin fusion proteins
WO1998046781A3 (en) Novel transgene expression system for increased persistence
HK1024714A1 (en) Dumbbell expression constructs for gene therapy
JP2002502831A5 (en)
WO1998034952A3 (en) Il-2 gene expression and delivery systems and uses
DK1783225T3 (en) Structural protein from AAV, its preparation and use
WO2003023000A3 (en) Linear dna fragments for gene expression
WO2003088899A3 (en) Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof
WO2000011151A3 (en) Direct oviduct transgenesis
ATE285239T1 (en) VACCINES CONTAINING DNA
CA2139948A1 (en) Targeting somatic gene therapy to joints
WO1996003506A3 (en) Analog of haemophilus hin47 with reduced protease activity
MXPA04004561A (en) A human matrix metalloproteinase and uses therefor.
CA2083396A1 (en) Derivatives of human bile-salt stimulated lipase, and pharmaceutical compositions containing them
KR20190067815A (en) Composition for alleviating or treating pain
HUP0101355A2 (en) Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2337496

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 562541

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999938769

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 53182/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999938769

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999938769

Country of ref document: EP